Hepatitis A virus transmission by blood products in the United States

J. W. Mosley; M. J. Nowicki; C. K. Kasper; E. Donegan; L. M. Aledort; M. W. Hilgartner; E. A. Operskalski; J. Gaiennie; M. Harris; H. Lee; M. C. Pike; D. O. Stram; M. Succar; Y. Zhou; S. H. Kleinman; S. L. Dietrich; J. M. Lusher; E. R. Schiff; M. A. Fletcher

doi:10.1159/000462666

Hepatitis A virus transmission by blood products in the United States

J. W. Mosley, M. J. Nowicki, C. K. Kasper, E. Donegan, L. M. Aledort, M. W. Hilgartner, E. A. Operskalski, J. Gaiennie, M. Harris, H. Lee, M. C. Pike, D. O. Stram, M. Succar, Y. Zhou, S. H. Kleinman, S. L. Dietrich, J. M. Lusher, E. R. Schiff, M. A. Fletcher

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

To address the question of HAV prevalence and seroconversion in relation to clotting factor concentrates, we assayed an early serum for 339 hemophiliacs followed every 6 months by the Transfusion Safety Study in the period from mid-1985 until mid-1992. We found 58.4% positive around entry, with an age-specific prevalence that did not vary with age. In comparison to rates for anti-HIV-negative blood donors, they were significantly higher. Based on testing of subsequent sera, 11 hemophiliacs (7.8% of 141 susceptibles) changed their anti-HAV status from negative to positive. In 9 instances, positivity immediately followed the first dose of intravenous immune globulin. A possible seroconversion followed treatment with blood components, and a possible seroconversion followed intermediate-purity, solvent/detergent(SD)-treated factor VIII concentrate. Neither of these 2 patients was anti-HAV IgM positive, so that passively transferred antibody is possible. The high prevalence among hemophiliacs at entry must be further investigated by determining the expected background rate in a US population similar to the hemophilia patients, and by comparing anti-HAV prevalence associated with SD-treated and heat-inactivated concentrates.

Original language	English
Pages (from-to)	24-28
Number of pages	5
Journal	Vox Sanguinis
Volume	67
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1159/000462666
State	Published - 1994
Externally published	Yes

Access to Document

10.1159/000462666

Cite this

Mosley, J. W., Nowicki, M. J., Kasper, C. K., Donegan, E., Aledort, L. M., Hilgartner, M. W., Operskalski, E. A., Gaiennie, J., Harris, M., Lee, H., Pike, M. C., Stram, D. O., Succar, M., Zhou, Y., Kleinman, S. H., Dietrich, S. L., Lusher, J. M., Schiff, E. R., & Fletcher, M. A. (1994). Hepatitis A virus transmission by blood products in the United States. Vox Sanguinis, 67(SUPPL. 1), 24-28. https://doi.org/10.1159/000462666

@article{cff662c208a744179851cd61352ec2f0,

title = "Hepatitis A virus transmission by blood products in the United States",

abstract = "To address the question of HAV prevalence and seroconversion in relation to clotting factor concentrates, we assayed an early serum for 339 hemophiliacs followed every 6 months by the Transfusion Safety Study in the period from mid-1985 until mid-1992. We found 58.4% positive around entry, with an age-specific prevalence that did not vary with age. In comparison to rates for anti-HIV-negative blood donors, they were significantly higher. Based on testing of subsequent sera, 11 hemophiliacs (7.8% of 141 susceptibles) changed their anti-HAV status from negative to positive. In 9 instances, positivity immediately followed the first dose of intravenous immune globulin. A possible seroconversion followed treatment with blood components, and a possible seroconversion followed intermediate-purity, solvent/detergent(SD)-treated factor VIII concentrate. Neither of these 2 patients was anti-HAV IgM positive, so that passively transferred antibody is possible. The high prevalence among hemophiliacs at entry must be further investigated by determining the expected background rate in a US population similar to the hemophilia patients, and by comparing anti-HAV prevalence associated with SD-treated and heat-inactivated concentrates.",

author = "Mosley, {J. W.} and Nowicki, {M. J.} and Kasper, {C. K.} and E. Donegan and Aledort, {L. M.} and Hilgartner, {M. W.} and Operskalski, {E. A.} and J. Gaiennie and M. Harris and H. Lee and Pike, {M. C.} and Stram, {D. O.} and M. Succar and Y. Zhou and Kleinman, {S. H.} and Dietrich, {S. L.} and Lusher, {J. M.} and Schiff, {E. R.} and Fletcher, {M. A.}",

year = "1994",

doi = "10.1159/000462666",

language = "English",

volume = "67",

pages = "24--28",

journal = "Vox Sanguinis",

issn = "0042-9007",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "SUPPL. 1",

}

Mosley, JW, Nowicki, MJ, Kasper, CK, Donegan, E, Aledort, LM, Hilgartner, MW, Operskalski, EA, Gaiennie, J, Harris, M, Lee, H, Pike, MC, Stram, DO, Succar, M, Zhou, Y, Kleinman, SH, Dietrich, SL, Lusher, JM, Schiff, ER & Fletcher, MA 1994, 'Hepatitis A virus transmission by blood products in the United States', Vox Sanguinis, vol. 67, no. SUPPL. 1, pp. 24-28. https://doi.org/10.1159/000462666

TY - JOUR

T1 - Hepatitis A virus transmission by blood products in the United States

AU - Mosley, J. W.

AU - Nowicki, M. J.

AU - Kasper, C. K.

AU - Donegan, E.

AU - Aledort, L. M.

AU - Hilgartner, M. W.

AU - Operskalski, E. A.

AU - Gaiennie, J.

AU - Harris, M.

AU - Lee, H.

AU - Pike, M. C.

AU - Stram, D. O.

AU - Succar, M.

AU - Zhou, Y.

AU - Kleinman, S. H.

AU - Dietrich, S. L.

AU - Lusher, J. M.

AU - Schiff, E. R.

AU - Fletcher, M. A.

PY - 1994

Y1 - 1994

N2 - To address the question of HAV prevalence and seroconversion in relation to clotting factor concentrates, we assayed an early serum for 339 hemophiliacs followed every 6 months by the Transfusion Safety Study in the period from mid-1985 until mid-1992. We found 58.4% positive around entry, with an age-specific prevalence that did not vary with age. In comparison to rates for anti-HIV-negative blood donors, they were significantly higher. Based on testing of subsequent sera, 11 hemophiliacs (7.8% of 141 susceptibles) changed their anti-HAV status from negative to positive. In 9 instances, positivity immediately followed the first dose of intravenous immune globulin. A possible seroconversion followed treatment with blood components, and a possible seroconversion followed intermediate-purity, solvent/detergent(SD)-treated factor VIII concentrate. Neither of these 2 patients was anti-HAV IgM positive, so that passively transferred antibody is possible. The high prevalence among hemophiliacs at entry must be further investigated by determining the expected background rate in a US population similar to the hemophilia patients, and by comparing anti-HAV prevalence associated with SD-treated and heat-inactivated concentrates.

AB - To address the question of HAV prevalence and seroconversion in relation to clotting factor concentrates, we assayed an early serum for 339 hemophiliacs followed every 6 months by the Transfusion Safety Study in the period from mid-1985 until mid-1992. We found 58.4% positive around entry, with an age-specific prevalence that did not vary with age. In comparison to rates for anti-HIV-negative blood donors, they were significantly higher. Based on testing of subsequent sera, 11 hemophiliacs (7.8% of 141 susceptibles) changed their anti-HAV status from negative to positive. In 9 instances, positivity immediately followed the first dose of intravenous immune globulin. A possible seroconversion followed treatment with blood components, and a possible seroconversion followed intermediate-purity, solvent/detergent(SD)-treated factor VIII concentrate. Neither of these 2 patients was anti-HAV IgM positive, so that passively transferred antibody is possible. The high prevalence among hemophiliacs at entry must be further investigated by determining the expected background rate in a US population similar to the hemophilia patients, and by comparing anti-HAV prevalence associated with SD-treated and heat-inactivated concentrates.

UR - http://www.scopus.com/inward/record.url?scp=0028234330&partnerID=8YFLogxK

U2 - 10.1159/000462666

DO - 10.1159/000462666

M3 - Article

C2 - 8091731

AN - SCOPUS:0028234330

SN - 0042-9007

VL - 67

SP - 24

EP - 28

JO - Vox Sanguinis

JF - Vox Sanguinis

IS - SUPPL. 1

ER -

Hepatitis A virus transmission by blood products in the United States

Abstract

Access to Document

Fingerprint

Cite this